Resumo

MEZA, Carolina et al. Tratamiento adyuvante en cáncer de colon: Nuestra experiencia. Rev. venez. oncol. [online]. 2011, vol.23, n.2, pp.66-75. ISSN 0798-0582.

Colon cancer is one of the most common tumors in our country. Following surgery, adjuvant chemotherapy has shown benefit for patients at high risk and node-positive, so it is considered standard modality. OBJECTIVE: The aim of this study is to evaluate the experience of our institution as far as this treatment modality, referred for five years. RESULTS: Preliminarily we evaluated total of 118 patients, the gender distribution was equal. Left colon tumors, occupied the highest percentage (45.76 %) and the most common histology was adenocarcinoma. With regard to TNM, T3 was the most frequent (53.1 %) and N0 also (46.9 %). Of the sample assessed, 63.2 % received adjuvant chemotherapy, being the most widely used schemes, Folfox 4 62.5 %, Xelox 18.1 % and Capecitabine 13.9 %. 66.7 % of patients had adverse events, being the most frequent diarrhea, nausea, vomiting, and peripheral neuropathy, all G1/2 in most cases. There were no treatment-related deaths. 100 % of patients had follow-up, for the year 2009, 55.93 % of them were alive. The OS was greater in the group that received adjuvant treatment with regard to that it did not receive it, without statistics significant (P=0.098) since up to the date there has not been reached the median of global survival. CONCLUSIONS: Similar results were obtained with regard to the DFS, being this major in the group that received chemotherapy, versus the group that did not receive it, reached significant statistics (P=0.045).

Palavras-chave : Colon; cancer; chemotherapy; adjuvant; overall survival; disease; free survival.